

Saturday, December 4, 2004

1:30 p.m. – 5:30 p.m.

Young Urologic Oncologist Forum

- 01:30 PM** **RADICAL PROSTATECTOMY FOR CLINICALLY ADVANCED (CT3) PROSTATE CANCER IN THE PSA ERA: 15-YEAR OUTCOMES**
John Ward, MD, Michael Blute, MD, Erik Bergstralh, Jeffrey Slezak and Horst Zincke, MD, PhD
(Presented By: John Ward, MD)
- 01:40 PM** **PROSTATE CANCER ON THE INTERNET: INFORMATION OR MISINFORMATION?**
Peter Black, MD and David Penson, MD (Presented By: Peter Black, MD)
- 01:50 PM** **QUALITY IMPROVEMENT IN LAPAROSCOPIC RADICAL PROSTATECTOMY FOR PT2 PROSTATE CANCER: IMPACT OF VIDEO DOCUMENTATION REVIEW ON POSITIVE SURGICAL MARGIN**
Karim Touijer, MD, Kentaro Kuroiwa, MD, Jeffery Saranchuk, MD, Waleed Hassen, MD, Edouard Trabulsi, MD, Victor Reuter, MD and Bertrand Guillonneau, MD (Presented By: Karim Touijer, MD)
- 02:00 PM** **PERSISTENT C-FLIP(L) EXPRESSION IS NECESSARY AND SUFFICIENT TO MAINTAIN RESISTANCE TO TRAIL-MEDIATED APOPTOSIS IN PROSTATE CANCER**
Xiaoping Zhang, MD, PhD, Tai-Guang Jin, PhD, Hongmei Yang, PhD, William DeWolf, MD, Roya Khosravi-Far, PhD and Aria Olumi, MD (Presented By: Aria Olumi, MD)
- 02:10 PM** **IMPACT OF NOX4 ON HIF-ALPHA EXPRESSION AND TRANSACTIVATION**
Jodi Maranchie, MD (Presented By: Jodi Maranchie, MD)
- 02:20 PM** **CYSTOPROSTATECTOMY FOR EFFECTIVE PALLIATION OF SYMPTOMATIC BLADDER INVASION BY PROSTATE CANCER**
Dan Leibovici, MD, Ashish Kamat, MD, Curtis Pettaway, MD, Lance Pagliaro, MD, Charles Rosser, MD, Christopher Logothetis, MD and Louis Pisters, MD (Presented By: Dan Leibovici, MD)
- 02:30 PM** **LONG-TERM OUTCOMES FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH CLINICAL T3 PROSTATE CANCER**
Brett Carver, MD, Fernando Bianco, MD, Peter Scardino, MD and James Eastham, MD
(Presented By: Brett Carver, MD)
- 02:40 PM** **MYCOPLASMA EFFECTS ON HUMAN TUMOR INVASION**
Satoshi Anai, MD, Susan Boehlein, PhD, Catherine Ketcham, PhD and Charles Rosser, MD
(Presented By: Satoshi Anai, MD)
- 02:50 PM** **TRANSITIONAL CELL CARCINOMA OF THE BLADDER IS INFILTRATED BY HIGH PROPORTIONS OF REGULATORY T-LYMPHOCYTES**
Maria Mercader-Bravo, BS, MS, PhD, Shomik Sengupta, MBBS, MSurg, FRACS, Haidong Dong, MD, PhD, Xavier Frigola, BS, Scott Webster, MD, R Houston Thompson, MD, Bradley Leibovich, MD, Horst Zincke, MD, PhD, Michael Blute, MD and Eugene Kwon, MD
(Presented By: Shomik Sengupta, MBBS, MSurg, FRACS)
- 03:00 PM** **RECOMBINANT PROSTATE CANCER VACCINES AND COMBINATION THERAPIES**
James Gulley, MD, PhD, Philip Arlen, MD, Nushin Todd, MD, PhD, William Dahut, MD, Kevin Camphausen, MD, C. Norman Coleman, MD and Jeffrey Schlom, PhD (Presented By: James Gulley, MD, PhD)
- 03:10 PM** **IMIQUIMOD, A TOLL-LIKE RECEPTOR AGONIST AND IMMUNE RESPONSE MODIFIER, INDUCES APOPTOSIS AND CYTOKINE PRODUCTION IN BLADDER CANCER CELL LINES**
Eric Smith, MD, Hidekiki Kawamoto, MD, Xuecke You, MD and Douglas Scherr, MD
(Presented By: Eric Smith, MD)

Continues on next page

17

YOUNG UROLOGIC ONCOLOGISTS FORUM

Continued from previous page

- 03:20 PM** **HIGH-THROUGHPUT CLINICAL ANALYSIS OF FOS RELATED ANTIGEN 1(FRA-1) EXPRESSION IN PROSTATE TUMORS: A NEW TUMOR MARKER IN PROSTATE CANCER**
Aaron Grotas, MD, John Phillips, MD, Mark Rafelled, MD, Lukas Bubendorf, MD and Eric Gerber, MD
(Presented By: Aaron Grotas, MD)
- 03:30 PM** **A PHASE II STUDY OF SEQUENTIAL VACCINATIONS WITH RFOWLPOX-PSA (L155)-TRICOM ALONE, OR IN COMBINATION WITH RVACCINIA-PSA (L155)-TRICOM, AND THE ROLE OF GM-CSF, IN PATIENTS (PTS) WITH METASTATIC ANDROGEN INSENSITIVE PROSTATE CANCER (AIPC)**
Nushin Todd, MD, PhD, James Gulley, MD, PhD, William Dahut, MD, Jeffrey Schlom, PhD and Philip Arlen, MD (Presented By: Nushin Todd, MD, PhD)
- 03:40 PM** **CLASSIFICATION AND TRENDS OF PERIOPERATIVE MORBIDITIES FOLLOWING LAPAROSCOPIC RADICAL PROSTATECTOMY**
Mark Gonzalgo, MD, PhD, Christian Pavlovich, MD, Matthew Gretzer, MD, Richard Link, MD, PhD, Sam Bhayani, MD, Wendy Sullivan and Li-Ming Su, MD (Presented By: Mark Gonzalgo, MD, PhD)
- 03:50 PM** **MANAGEMENT AND FOLLOW-UP OF PATIENTS WITH CARCINOMA IN SITU AT A POSITIVE DISTAL URETERAL MARGIN FOLLOWING RADICAL CYSTECTOMY**
Albert Ong, MD, Richard Link, MD, Sam Bhayani, MD, Ioannis Varkarakis, MD, Mohammad Allaf, MD, Mark Schoenberg, MD and Thomas Jarrett, MD (Presented By: Albert Ong, MD)
- 04:00 PM** **ANALYSIS OF 14-3-3 PROTEINS IN PROSTATE CANCER.**
Michael Karellas, MD, Xinbo Liao, PhD, Jeffrey Holzbeierlein, MD, J. Brantley Thrasher, MD and Benyi Li, MD, PhD (Presented By: Michael Karellas, MD)
- 04:10 PM** **NEOADJUVANT CHEMOTHERAPY DOES NOT INCREASE COMPLICATION RATE AFTER RADICAL CYSTECTOMY**
Rabii Madi, MD, James Montie, MD, David Smith, MD, David Wood, MD, Stephanie Faruzzi, MS, Yingxi Zhang, MS and Cheryl Lee, MD (Presented By: Rabii Madi, MD)
- 04:20 PM** **MOUSE MODEL FOR BLADDER CANCER INDUCTION AND IMAGING**
Isla Garraway, MD, PhD, Chau Tran, PhD, Katie Cai and Robert Reiter, MD
(Presented By: Isla Garraway, MD, PhD)
- 04:30 PM** **EFFICACY OF COMBINING SELECTIVE ESTROGEN RECEPTOR MODULATORS AND CASODEX™ IN ANDROGEN-DEPENDENT PROSTATE CANCER CELLS**
Melissa M. Walls, MD, Asim Abdel-Mageed, DVM, PhD, Rodney Davis, MD and Erik P. Castle, MD
(Presented By: Erik P. Castle, MD)
- 04:40 PM** **EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A), VEGF RECEPTOR 1 (VEGFR-1) AND VEGFR-2 IN CLEAR CELL AND PAPILLARY RENAL CELL CARCINOMA (RCC): IMPLICATIONS FOR THERAPY**
John Leppert, MD, John Lam, MD, Hong Yu, David Seligson, MD, Jun Dong, PhD, Steve Horvath, PhD, Allan Pantuck, MD, Robert Figlin, MD and Arie Belldegrun, MD (Presented By: John Leppert, MD)
- 04:50 PM** **CLINICAL OUTCOMES OF PATIENTS DOWNSTAGED AT RADICAL CYSTECTOMY**
Craig Rogers, MD, Patrick Bastian, MD, Ganesh Palapattu, MD, Bruce Trock, PhD, Mark Schoenberg, MD and Theresa Chan, MD (Presented By: Craig Rogers, MD)

5:30 p.m.

Adjourn